MarketCap
Facebook
X
TelegramQuarterly report 2024-Q3
added 10-29-2024
10x Genomics Deferred Revenue 2011-2025 | TXG
Deferred revenue is the amount of money or obligations that a company has received in advance for goods or services that have not yet been delivered or performed. In other words, it is income that has already been received but has not yet been recognized in accounting as revenue because the goods or services have not yet been transferred to the customer.Features of the metric
- Sources of future cash inflows
A high level of deferred revenue indicates that the company has secured future cash flows, which positively affects forecasts of its financial condition and stability. - Assessment of operational stability
Deferred revenue reflects demand for the company’s products or services and its ability to attract customers willing to pay in advance. It is one of the indicators of business stability and its competitive advantages. - Risks and obligations
Although deferred revenue indicates future inflows, it also represents obligations that the company must fulfill. If fulfilling these obligations is delayed or impossible, it can negatively impact reputation and financial results. - Analysis of liquidity and cash flow
Inflows in the form of deferred revenue improve the company’s current liquidity since the funds are already in the accounts. However, investors need to assess the ratio of deferred revenue to fulfilled obligations to understand the actual financial capabilities and risks. - Impact on company valuation
In fundamental analysis, deferred revenue is taken into account for accurate revenue and profit forecasting, especially in industries with long-term contracts or subscriptions (e.g., IT sector, services, manufacturing).
Annual Deferred Revenue 10x Genomics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 13.2 M | 7.87 M | 5.34 M | 4.47 M | 4.6 M | 2.78 M | 1.83 M | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 13.2 M | 1.83 M | 5.72 M |
Quarterly Deferred Revenue 10x Genomics
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 17.8 M | 16.4 M | 14.3 M | - | - | 8.53 M | 7.87 M | - | 6.47 M | 5.43 M | 5.34 M | 5.5 M | 5.27 M | 4.48 M | 4.47 M | 4.47 M | 4.47 M | 4.47 M | 3.3 M | 3.3 M | 3.3 M | 3.3 M | 2.4 M | 2.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 17.8 M | 2.4 M | 6.35 M |
Deferred Revenue of other stocks in the Health information services industry
| Issuer | Deferred Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Cerner Corporation
CERN
|
531 M | - | - | $ 27.9 B |  USA |
 |
Computer Programs and Systems
CPSI
|
8.68 M | - | 4.4 % | $ 133 M | USA |
 |
Covetrus
CVET
|
28 M | - | - | $ 2.94 B | USA |
 |
Accolade
ACCD
|
25.9 M | - | 0.29 % | $ 206 M | USA |
 |
Castlight Health, Inc.
CSLT
|
6.85 M | - | -7.28 % | $ 227 M | USA |
 |
Inovalon Holdings, Inc.
INOV
|
10.9 M | - | - | $ 6.37 B | USA |
 |
Change Healthcare
CHNG
|
469 M | - | - | $ 9.03 B | USA |
 |
Evolent Health
EVH
|
5.76 M | $ 4.11 | -0.48 % | $ 385 M | USA |
 |
Health Catalyst
HCAT
|
53.3 M | $ 2.34 | -4.82 % | $ 141 M | USA |
 |
HealthStream
HSTM
|
84.2 M | $ 24.4 | 0.95 % | $ 741 M | USA |
 |
iCAD
ICAD
|
3.86 M | - | - | $ 102 M | USA |
 |
Akerna Corp.
KERN
|
569 K | - | - | $ 161 M | USA |
 |
OptimizeRx Corporation
OPRX
|
172 K | $ 13.18 | -1.35 % | $ 226 M | USA |
 |
American Well Corporation
AMWL
|
53.2 M | $ 4.68 | 1.3 % | $ 70.2 M | USA |
 |
Allscripts Healthcare Solutions
MDRX
|
326 M | - | -10.39 % | $ 886 M | USA |
 |
Premier
PINC
|
22.5 M | $ 28.26 | - | $ 2.33 B | USA |
 |
MTBC
MTBC
|
1.21 M | - | -0.58 % | $ 51.7 M | USA |
 |
GoodRx Holdings
GDRX
|
6.04 M | $ 2.72 | -3.72 % | $ 1.05 B | USA |
 |
Schrödinger
SDGR
|
112 M | $ 18.41 | 1.99 % | $ 1.34 B | USA |
 |
Omnicell
OMCL
|
141 M | $ 43.31 | -1.25 % | $ 1.99 B | USA |
 |
1Life Healthcare
ONEM
|
47.9 M | - | - | $ 3.37 B | USA |
 |
Phreesia
PHR
|
24.1 M | $ 16.68 | 2.71 % | $ 910 M | USA |
 |
So-Young International
SY
|
135 M | $ 2.92 | -5.66 % | $ 232 M |  China |
 |
Signify Health
SGFY
|
2.4 M | - | -0.02 % | $ 7.21 B | USA |
 |
R1 RCM
RCM
|
83.9 M | - | - | $ 3.81 B | USA |
 |
NantHealth
NH
|
2.72 M | - | -46.64 % | $ 10.4 M | USA |
 |
NextGen Healthcare
NXGN
|
52.9 M | - | - | $ 1.6 B | USA |
 |
Veeva Systems
VEEV
|
1.05 B | $ 219.17 | -1.81 % | $ 35.2 B | USA |
 |
Zhongchao
ZCMD
|
6.76 K | $ 0.58 | -3.18 % | $ 3.02 M | China |
 |
Streamline Health Solutions
STRM
|
6.1 M | - | - | $ 21.4 M | USA |
 |
Teladoc Health
TDOC
|
79.3 M | $ 7.36 | -2.65 % | $ 1.26 B | USA |
 |
Tabula Rasa HealthCare
TRHC
|
4.86 M | - | - | $ 255 M | USA |
 |
SCWorx Corp.
WORX
|
354 K | $ 0.21 | 5.86 % | $ 306 K | USA |